The Innovative Medicines Initiative (IHI) has funded more than 20 projects so far that are tackling Alzheimer’s disease.IHI held a workshop in 2025 examining project outcomes, challenges and opportunities regarding neurodegenerative diseases in Europe. The workshop examined how the public-private partnership model has worked in various IMI and IHI projects, and identified hot topics and key areas where public-private research could have an impact in the future, building on what has been delivered so far.

The workshop’s first session explored the challenges that stand in the way of neurodegenerative research and innovation that public-private partnerships (PPPs) such as the IHI could address. Several speakers emphasised the unique value that PPPs such as IHI bring to this field. Then, different topics were addressed, including clinical trials, data solutions, digital innovation and healthcare preparedness.

Gill Farrar of GE Healthcare launched the discussion on diagnosis and disease interception by outlining the impact of the AMYPAD project, in particular describing how achieving one of the project’s regulatory goals delivered longer lasting impact than they had imagined. Frederik Barkhof of the Amsterdam University Medical Centre, who co-led AMYPAD, noted that AMYPAD built lasting infrastructures, saying: “the AMYPAD community still work together on EPAD and AMYPAD data with the help of ADDI, producing new impactful outputs.”

You can read the report of the event here: https://www.ihi.europa.eu/news-events/newsroom/how-public-private-partnerships-can-help-tackle-neurodegenerative-diseases